Literature DB >> 22434312

Circulating biomarkers in advanced renal cell carcinoma: clinical applications.

Maria Hernandez-Yanez1, John V Heymach, Amado J Zurita.   

Abstract

Advances in understanding the biology of renal cell carcinoma (RCC) have resulted in treatment strategies based on molecularly targeted agents that have substantially improved the outcomes of patients with metastatic RCC. Agents targeting the vascular endothelial growth factor pathway and the mammalian target of rapamycin have shown efficacy in randomized clinical trials and received international approval for treating RCC. Multiple candidate biomarkers of the biologic activity of such targeted therapies as well as markers of treatment response and patients' prognosis are being evaluated to improve drug development and to identify patients who may obtain the greatest benefit from the various treatment options. This review summarizes recent developments in identifying circulating biomarkers of targeted therapies for metastatic RCC, including soluble proteins and circulating cells.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22434312      PMCID： PMC3872150          DOI： 10.1007/s11912-012-0231-2

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  89 in total

1.  Pharmacokinetic/pharmacodynamic modeling of biomarker response to sunitinib in healthy volunteers.

Authors:  A Lindauer; P Di Gion; F Kanefendt; D Tomalik-Scharte; M Kinzig; M Rodamer; F Dodos; F Sörgel; U Fuhr; U Jaehde
Journal:  Clin Pharmacol Ther       Date:  2010-04-07       Impact factor: 6.875

Review 2.  Macrophage diversity enhances tumor progression and metastasis.

Authors:  Bin-Zhi Qian; Jeffrey W Pollard
Journal:  Cell       Date:  2010-04-02       Impact factor: 41.582

3.  Cytogenetic features, clinical significance and prognostic impact of type 1 and type 2 papillary renal cell carcinoma.

Authors:  Alessandro Antonelli; Regina Tardanico; Piera Balzarini; Nicola Arrighi; Laura Perucchini; Tiziano Zanotelli; Alberto Cozzoli; Danilo Zani; Sergio Cosciani Cunico; Claudio Simeone
Journal:  Cancer Genet Cytogenet       Date:  2010-06

4.  Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial.

Authors:  Martin E Gore; Clare L Griffin; Barry Hancock; Poulam M Patel; Lynda Pyle; Michael Aitchison; Nicholas James; Roderick T D Oliver; Jozef Mardiak; Tahera Hussain; Richard Sylvester; Mahesh K B Parmar; Patrick Royston; Peter F A Mulders
Journal:  Lancet       Date:  2010-02-10       Impact factor: 79.321

Review 5.  Alterations in VHL as potential biomarkers in renal-cell carcinoma.

Authors:  Lucy Gossage; Tim Eisen
Journal:  Nat Rev Clin Oncol       Date:  2010-04-06       Impact factor: 66.675

6.  Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.

Authors:  Bernard Escudier; Joaquim Bellmunt; Sylvie Négrier; Emilio Bajetta; Bohuslav Melichar; Sergio Bracarda; Alain Ravaud; Sophie Golding; Sangeeta Jethwa; Vesna Sneller
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

7.  Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib.

Authors:  Petros G Nikolinakos; Nasser Altorki; David Yankelevitz; Hai T Tran; Shaoyu Yan; Dilip Rajagopalan; Walter Bordogna; Lone H Ottesen; John V Heymach
Journal:  Cancer Res       Date:  2010-03-09       Impact factor: 12.701

8.  Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained.

Authors:  Jennifer S Ko; Patricia Rayman; Joanna Ireland; Shadi Swaidani; Geqiang Li; Kevin D Bunting; Brian Rini; James H Finke; Peter A Cohen
Journal:  Cancer Res       Date:  2010-04-20       Impact factor: 12.701

Review 9.  Elusive identities and overlapping phenotypes of proangiogenic myeloid cells in tumors.

Authors:  Seth B Coffelt; Claire E Lewis; Luigi Naldini; J Martin Brown; Napoleone Ferrara; Michele De Palma
Journal:  Am J Pathol       Date:  2010-02-18       Impact factor: 4.307

10.  Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma.

Authors:  Min-Han Tan; Chin Fong Wong; Hwei Ling Tan; Ximing J Yang; Jonathon Ditlev; Daisuke Matsuda; Sok Kean Khoo; Jun Sugimura; Tomoaki Fujioka; Kyle A Furge; Eric Kort; Sophie Giraud; Sophie Ferlicot; Philippe Vielh; Delphine Amsellem-Ouazana; Bernard Debré; Thierry Flam; Nicolas Thiounn; Marc Zerbib; Gérard Benoît; Stéphane Droupy; Vincent Molinié; Annick Vieillefond; Puay Hoon Tan; Stéphane Richard; Bin Tean Teh
Journal:  BMC Cancer       Date:  2010-05-12       Impact factor: 4.430
View more
  13 in total

1.  Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma.

Authors:  Toni K Choueiri; Mayer N Fishman; Bernard Escudier; David F McDermott; Charles G Drake; Harriet Kluger; Walter M Stadler; Jose Luis Perez-Gracia; Douglas G McNeel; Brendan Curti; Michael R Harrison; Elizabeth R Plimack; Leonard Appleman; Lawrence Fong; Laurence Albiges; Lewis Cohen; Tina C Young; Scott D Chasalow; Petra Ross-Macdonald; Shivani Srivastava; Maria Jure-Kunkel; John F Kurland; Jason S Simon; Mario Sznol
Journal:  Clin Cancer Res       Date:  2016-05-11       Impact factor: 12.531

2.  Detection of circulating tumour cells and their potential use as a biomarker for advanced renal cell carcinoma.

Authors:  Tae Heon Kim; Yoon-Tae Kang; Young-Ho Cho; Jeong Hoon Kim; Byong Chang Jeong; Seong Il Seo; Seong Soo Jeon; Hyun Moo Lee
Journal:  Can Urol Assoc J       Date:  2019-01-21       Impact factor: 1.862

3.  Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.

Authors:  Anish Thomas; Arun Rajan; Arlene Berman; Yusuke Tomita; Christina Brzezniak; Min-Jung Lee; Sunmin Lee; Alexander Ling; Aaron J Spittler; Corey A Carter; Udayan Guha; Yisong Wang; Eva Szabo; Paul Meltzer; Seth M Steinberg; Jane B Trepel; Patrick J Loehrer; Giuseppe Giaccone
Journal:  Lancet Oncol       Date:  2015-01-13       Impact factor: 41.316

4.  Next-generation technologies for spatial proteomics: Integrating ultra-high speed MALDI-TOF and high mass resolution MALDI FTICR imaging mass spectrometry for protein analysis.

Authors:  Jeffrey M Spraggins; David G Rizzo; Jessica L Moore; Michael J Noto; Eric P Skaar; Richard M Caprioli
Journal:  Proteomics       Date:  2016-05-10       Impact factor: 3.984

5.  Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma.

Authors:  Bishoy A Gayed; Jessica Gillen; Alana Christie; Samuel Peña-Llopis; Xian-Jin Xie; Jingsheng Yan; Jose A Karam; Ganesh Raj; Arthur I Sagalowsky; Yair Lotan; Vitaly Margulis; James Brugarolas
Journal:  BMC Urol       Date:  2015-04-03       Impact factor: 2.264

6.  Circulating Tumor Cell Composition in Renal Cell Carcinoma.

Authors:  Ivonne Nel; Thomas C Gauler; Kira Bublitz; Lazaros Lazaridis; André Goergens; Bernd Giebel; Martin Schuler; Andreas-Claudius Hoffmann
Journal:  PLoS One       Date:  2016-04-21       Impact factor: 3.240

7.  Are morphological criteria sufficient for the identification of circulating tumor cells in renal cancer?

Authors:  Amin El-Heliebi; Thomas Kroneis; Evelyn Zöhrer; Johannes Haybaeck; Katja Fischereder; Karin Kampel-Kettner; Richard Zigeuner; Hannelore Pock; Regina Riedl; Rudolf Stauber; Jochen Bernd Geigl; Berthold Huppertz; Peter Sedlmayr; Carolin Lackner
Journal:  J Transl Med       Date:  2013-09-17       Impact factor: 5.531

8.  Co-expression of pregnane X receptor and ATP-binding cassette sub-family B member 1 in peripheral blood: A prospective indicator for drug resistance prediction in non-small cell lung cancer.

Authors:  Qingnuan Kong; Zenglei Han; Xiaoli Zuo; Hongjun Wei; Weiqing Huang
Journal:  Oncol Lett       Date:  2016-03-22       Impact factor: 2.967

9.  Label-free detection of rare circulating tumor cells by image analysis and machine learning.

Authors:  Shen Wang; Yuyuan Zhou; Xiaochen Qin; Suresh Nair; Xiaolei Huang; Yaling Liu
Journal:  Sci Rep       Date:  2020-07-22       Impact factor: 4.379

10.  Detection of Circulating Tumor Cells in Renal Cell Carcinoma: Disease Stage Correlation and Molecular Characterization.

Authors:  Petr Klezl; Eliska Pospisilova; Katarina Kolostova; Jindrich Sonsky; Ondrej Maly; Robert Grill; Ireneusz Pawlak; Vladimir Bobek
Journal:  J Clin Med       Date:  2020-05-07       Impact factor: 4.241
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.